Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regeneus Ltd. ( (AU:CMB) ) has shared an announcement.
Cambium Bio Limited has announced a proposed placement of up to 4,363,637 new fully paid ordinary shares on the ASX, with an expected issue date of 17 March 2026. The capital raising signals an effort to strengthen the company’s balance sheet and support ongoing activities, a common approach among smaller biotech issuers seeking funds for development pipelines and operational needs, and will modestly dilute existing shareholders while potentially improving the company’s financial flexibility and market positioning.
The most recent analyst rating on (AU:CMB) stock is a Sell with a A$0.44 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited, listed on the ASX under the code CMB, operates in the biotechnology sector. While this filing does not detail its specific products or services, the company’s activities are consistent with early-stage life sciences businesses that rely on equity capital raisings to fund research, development and corporate operations.
Average Trading Volume: 3,284
Technical Sentiment Signal: Sell
Current Market Cap: A$10.57M
Find detailed analytics on CMB stock on TipRanks’ Stock Analysis page.